Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Get a window into what the leading players across the biopharma, medtech, and diagnostics industries are thinking, as well as important insight into what your competitors are doing. Build your strategy with In Vivo.
Construct winning strategies that anticipate where value will lie. In Vivo’s in-depth analysis spans influential deals, R&D, commercial and market access strategies.
How it helps
With In Vivo, you’ll benefit from:
How it works
Access mission-critical information via a simple-to-use interface. And if you need to need to find out more about developments or pharmaceutical industry trends to support presentations, proposals or business-critical decisions, you can access our worldwide network of expert analysts through our acclaimed Ask-the-Analyst™ service.
Plus, you can identify threats and opportunities using our Execs on the Move feature, which tracks the company movements of senior executives.
In Vivo
17 Sep 2019
With more individualized treatments, such as cell and gene therapies, coming to market every day, In Vivo can keep you up to date on the diversity within clinical R&D, trials, the latest trends and the barriers that still exist within personalised medicine. We’ve pulled together information covering the increasing focus of personalized medicine in clinical R&D and the future trends of precision medicine.
Topic Personalized Medicine
In Vivo
16 Sep 2019
With more individualized treatments, such as cell and gene therapies, coming to market every day, In Vivo can keep you up to date on the diversity within clinical R&D, trials, the latest trends and the barriers that still exist within personalised medicine. We’ve pulled together a helpful infographic to summaries these changes.
Topic Personalized Medicine
In Vivo
23 Aug 2019
Explore the six biggest therapeutic R&D challenges facing the industry today with a free infographic from In Vivo. This snapshot view of the major issues facing R&D is packed with data and insights about everything from drug resistance to diagnostics challenges.
In Vivo
21 Aug 2019
There are many ways to market your brand and establish your business as a thought leader - but none of these methods compare to the distinct advantage gained through marketing with In Vivo and Informa Pharma Intelligence. The articles, news and interviews we feature are used daily by senior decision-makers to support their decisions, and to keep abreast of what their competitors are doing.
Topic Business strategies Medtech
In Vivo
By Ashley Yeo 16 Aug 2019
In a world where national economies are beset by conflicting spending priorities, health care is oftentimes too low on the agenda, health care observers say. One of these is Boston Scientific senior vice-president Eric Thépaut, who understands the dilemmas, but says that health care will soon force its way up the priority list. He has advice for future-ready medtech innovators.
Topic Medtech Business strategies
In Vivo
By Melanie Senior 08 Aug 2019
Scientists now understand that there are multiple, bi-directional links between gut and brain. They are using this knowledge to develop new treatments for some of the most challenging chronic conditions, including Alzheimer’s disease, Parkinson’s disease and obesity.
Topic Diseases
In Vivo
31 Jul 2019
Get exclusive info on the leaders of the Pharma industry.The 2019 Titan of Pharma infographic is a snapshot of the industry’s top leaders and the businesses they oversee.
Topic Company analysis Strategy
In Vivo
By William Looney 30 Jul 2019
In today’s globalized market for medicines, national rules on pricing and access are abundantly shared and more transparent than opaque. In Vivo speaks to the UK branded industry’s negotiator for the latest five-year joint pricing pact with the government, Richard Torbett, who outlines, among other topics, five widely applicable precedents from the talks that can work in “getting to yes” – despite the fractious budgetary climate for health care evident in all major country markets.
Topic Brexit Policy and regulation
Scrip, In Vivo
25 Jul 2019
AstraZeneca’s pact with the UK-based artificial intelligence leader BenevolentAI, in April 2019, is one component in a string of recent deals that have highlighted big pharma’s desire to embed AI and machine learning within the R&D process. In total, 13 such collaborations have been tracked in the past 24 months, according to the Strategic Transactions database.
Topic Digital Health Strategy Medtech
In Vivo
By Ashley Yeo 12 Jul 2019
Medtech’s contribution to health care improvements in Europe over the past 30 years has been a phenomenal journey of success – in patient terms as well as in commercial terms, says MedTech Europe chair Rob ten Hoedt. Local creativity has been able to mine a seam of product innovation that is unmatched anywhere in the world, but the sector is facing massive change and must find ways to cope.
Topic Medtech Digital Health
In Vivo
By Sanskriti Thakur and Gordon Murphy 04 Jul 2019
Finding innovative ways to adapt the biopharma business model to external and internal challenges is a key competitive differentiator for today’s C-suite leadership.
Topic BioPharmaceutical Research
In Vivo
02 Jul 2019
No NASH treatments are on the market yet, but Phase III data readouts are emerging, mid-stage drugs are demonstrating their capabilities and combinations are in view.
Topic Clinical trials
In Vivo
By Mandy Jackson 02 Jul 2019
Medical aesthetics is a unique biopharmaceutical niche that may scare off companies due to the consumer marketing and doctor relationship-building skills needed to compete in this market, but the potential for growth keeps major players engaged and searching for new technology.
Topic BioPharmaceutical
In Vivo
By Lucie Ellis 02 Jul 2019
With both a big pharma and biotech leadership perspective, David Meeker talks to In Vivo about how smaller firms can more easily fly solo in drug development, challenges effecting the innovative drug development sector in 2019 and the partnering environment for cell and gene therapy companies.
Topic BioPharmaceutical Drug approval Drug development landscape Drug review
In Vivo
By William Looney 02 Jul 2019
The clinical trial embodies the hope and the hassle of biopharma’s mission to develop new drugs for patients. It is an endlessly imperfect process: C-suite calls for more efficiency and speed at lower cost has been the story for decades. But an In Vivo conversation with a leading expert on trial management pinpoints three key trends that suggest better days are ahead for this central pillar of the innovation imperative.
Topic Clinical trials
In Vivo
11 Sep 2019
In Vivo
11 Sep 2019
In Vivo
06 Sep 2019
In Vivo
04 Sep 2019
In Vivo
04 Sep 2019
In Vivo
04 Sep 2019
In Vivo
02 Sep 2019
In Vivo
27 Aug 2019
In Vivo
21 Aug 2019
In Vivo
19 Aug 2019
In Vivo
16 Aug 2019
In Vivo
14 Aug 2019
In Vivo
12 Aug 2019
In Vivo
12 Aug 2019
In Vivo
09 Aug 2019
William specializes in
+39 year(s) experience
Washington DC
Cathy specializes in
+38 year(s) experience
Washington DC
Denise specializes in
+37 year(s) experience
Request a Trial
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
How can we help you?
Our team is always happy to hear from you. Please call us at:
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
Keep up to date